Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Delayed Quote. Delayed Swiss Exchange - 08/23 11:30:14 am
87.34 CHF   -0.48%
08/23Health Care Falls on Flight From Risk -- Health Care Roundup
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : names Bulto as new head of U.S. drugs business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 08:54am EDT
Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel

ZURICH (Reuters) - Swiss drugmaker Novartis has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1.

He replaces Fabrice Chouraqui, who will step down at the end of August, Novartis said in a statement.

It gave no reason for the switch, which comes as the drugmaker faces U.S. scrutiny over its handling of a case of manipulated data linked to its $2 million per treatment gene therapy, Zolgensma.

A spokesman said the two matters were not related.

The statement said Chouraqui had "consistently demonstrated strong leadership, ethics and integrity" during his tenure.

Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year company veteran who has worked across every therapeutic area at the group and helped launch several products, including top-selling inflammation drug Cosentyx in the U.S. market.

(Reporting by Paul Arnold Writing by Michael Shields; Editing by Stephen Powell)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
08/23Health Care Falls on Flight From Risk -- Health Care Roundup
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/23NOVARTIS : Delay on Data Manipulation Probed
DJ
08/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/22NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/22NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/22NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/20GLANCY PRONGAY & MURRAY LLP : Continues its Investigation on Behalf of Novartis ..
BU
More news
Financials (USD)
Sales 2019 46 912 M
EBIT 2019 13 831 M
Net income 2019 9 752 M
Debt 2019 17 515 M
Yield 2019 3,32%
P/E ratio 2019 20,6x
P/E ratio 2020 21,5x
EV / Sales2019 4,74x
EV / Sales2020 4,38x
Capitalization 205 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 94,22  $
Last Close Price 89,45  $
Spread / Highest target 20,1%
Spread / Average Target 5,33%
Spread / Lowest Target -9,35%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS18.13%204 739
JOHNSON & JOHNSON-1.02%337 101
ROCHE HOLDING LTD.11.71%237 836
MERCK AND COMPANY11.16%217 478
PFIZER-19.63%189 936
NOVO NORDISK AS19.12%125 435